Wenying Yang

18PUBLICATIONS
24CO-AUTHORS
Innate immunityPredictive and prognostic markersPharmacogenomicsOpen accessApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Feb 27, 2025
iGlarLixi provides improved early glycaemic control after 12 weeks of treatment compared with basal insulin in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN studies.

Lulu Song, Xiaoyong Yuan, Shan Huang

|Nov 29, 2024
Development of a predictive model for gastrointestinal side effects of metformin treatment in Chinese individuals with type 2 diabetes based on four randomised clinical trials.

Weihao Wang, Yujia Han, Xun Jiang

|Apr 15, 2024
Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial.

Yao Wang, Chengxia Jiang, Xiaolin Dong

|Jan 03, 2024
Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials.

Wenying Yang, Xiaohui Guo, Felipe Lauand

|Mar 31, 2023
iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.

Xiaohui Guo, Wenying Yang, Junqing Zhang

|Dec 14, 2022
Yogliptin monotherapy in type 2 diabetes: A 12-week randomized, double-blind, placebo-controlled phase II study.

Xin Wang, Ying Wang, Xiaolan Yong

Pageof 3

Frequent Collaborators

2 joint publications

Xiaomu Kong

2 joint publications

Li Chen

2 joint publications

Ming Liu

2 joint publications

Dalong Zhu